Drug Repurposing in Pancreatic Cancer: A Multi-Stakeholder Perspective to Improve Treatment Options for Pancreatic Cancer Patients
Year: 2025
Type: article
Abstract: : Pancreatic cancer (PC) remains one of the most challenging malignancies to treat. Current therapeutic options are unsatisfactory, and there is an urgent need for more effective and less toxic drugs to improve the dismal prognosis of PC. In recent years, drug repurposing (DR) has emerged as an attractive strategy to identify novel treatments for PC by leveraging existing drugs approved for other indications. Through the use of electronic medical records, Artificial Intelligence, study of metabolic pathways, signalling pathways, and many other approaches, it has become much easier in recent years to identify potential novel uses for old drugs. Although policy, funding and research attention in this area are steadily growing, major challenges to efficient and effective patient-centric DR in PC need to be addressed. These include but are not limited to regulatory, financial and funding barriers and the lack of coordination and collaboration among several sectors and stakeholders. To explore the opportunities and challenges associated with DR in PC, a one-day multi-stakeholder meeting was held on 14 th of November 2024 in Brussels, Belgium as part of the REMEDi4ALL project. This meeting provided a platform for researchers, clinicians, industry representatives, funders, regulatory experts, and patient advocates to discuss and propose actions to optimize and accelerate DR in PC. Insights from this meeting support the potential of DR to enhance PC treatment options while highlighting the importance of systemic and supportive changes in the regulatory, policy and funding landscapes, interdisciplinary collaboration, data sharing, and patient involvement in driving therapeutic innovation. This summary highlights key outcomes and recommendations from the meeting in informing future efforts to advance DR initiatives in the context of PC. Keywords: drug repurposing, pancreatic cancer, multi-stakeholder discussion, collaboration, patient centricity
Source: Cancer Management and Research
DOI: 10.2147/cmar.s483151
Authors: Evelyn Hewitt, Gauthier Bouche, Alexandre Alencar, Stephen Bigelsen, Raluca Radu, Violeta Stoyanova-Beninska, Alfredo Carrato, Federica Valsecchi, Alicia Soler Cantón, Helene van der Meer, María García Bermejo, Alfredo Budillon, Luca Cardone, Ilse Rooman, Hans Platteeuw, Judit Baijet, Claudia Fuchs
Institutions: Anticancer Fund, Rising Tide Foundation, Rutgers New Jersey Medical School, Medicines Evaluation Board, Universidad de Alcalá, Instituto Ramón y Cajal de Investigación Sanitaria, Centro de Investigación Biomédica en Red de Cáncer, Hospital Universitario Ramón y Cajal, Fondazione Nadia Valsecchi, European Infrastructure for Translational Medicine, ZonMw, The Dutch Organisation for knowledge and innovation in health, healthcare and well-being, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", National Research Council, Instituto Nazionale Tumori Regina Elena, Vrije Universiteit Brussel, European Organisation for Rare Diseases
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,836
Funder: European Commission
OpenAlex ID: W4408078469
